-
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
Tuesday, January 23, 2024 - 8:46am | 641Read More...In a strategic move to bolster its rare disease business, Sanofi SA (NASDAQ:SNY) has agreed to acquire the drug development project INBRX-101 from its parent company, Inhibrx Inc (NASDAQ:INBX). This acquisition is valued at approximately $2.2 billion. What Happened: The French healthcare company...
-
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Friday, May 19, 2023 - 1:56pm | 849Read More...On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel narrowly recommended approval for the company's gene therapy for Duchenne Muscular Dystrophy (DMD)....
-
Big Pharma's Sanofi Enters Licencing Agreement With Private Psychedelics Company Terran
Monday, April 25, 2022 - 12:17pm | 509Read More...Terran Biosciences is slowly but surely finding its place in the psychedelics industry. Last week, the company announced a licensing agreement with Big Pharma’s heavy-weight Sanofi (NASDAQ: SNY). Founded in 2017, Terran has maintained a low profile until recently. In early...
-
Fintech Focus For July 3, 2020
Friday, July 3, 2020 - 9:26am | 1689Read More...Daily Perspective: Life is what happens when you're busy making other plans. - John Lennon Fintech Movers: An International Monetary Fund (IMF) official recently noted that China’s Fintech sector could be “instrumental” in assisting SMEs with acquiring reliable credit. The...
-
Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings
Friday, November 3, 2017 - 1:52pm | 507Read More...Ahead of Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s quarterly report, scheduled for Wednesday, Nov. 8, the company's shares won an upgrade. Regeneron shares fell beneath Baird's price target after an August downgrade, analyst Brian Skorney said in a Friday note. With better-than-...
-
Expectations For Regeneron No Longer Realistic; Analyst Downgrades
Tuesday, August 1, 2017 - 9:58am | 334Read More...Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....
-
Sanofi Names Candidates, Committed To Replacing Medivation's Entire Board
Wednesday, May 25, 2016 - 9:04am | 305Read More...Reuters reported early Wednesday morning that Sanofi SA (ADR) (NYSE: SNY) is preparing a list of candidates it plans to put forward to replace Medivation Inc (NASDAQ: MDVN)'s entire board of directors. Sanofi has threatened to do so after Medivation rejected its $9.3 billion bid to acquire the...
-
Here's What Medivation Said In Its Rejection Letter To Sanofi
Friday, April 29, 2016 - 2:38pm | 361Read More...Medivation Inc (NASDAQ: MDVN) disclosed on Friday a letter it has written to Sanofi SA (ADR) (NYSE: SNY) with regards to its acquisition offer to buy the company for $52.50 per share. Medivation started off by stating its Board of Directors unanimously rejected Sanofi's proposal to fully...
-
Sanofi Wants To Acquire Medivation For $52.50 Per Share
Thursday, April 28, 2016 - 10:11am | 271Read More...Sanofi SA (ADR) (NYSE: SNY) announced on Thursday that it has sent a letter to Medivation Inc (NASDAQ: MDVN) in which it confirmed an offer to acquire the company for $52.50 per share was proposed on April 15 and initial discussions regarding a merger were held in late March. Shares of Medivation...
-
Big Biotech In The Earnings Spotlight
Tuesday, April 26, 2016 - 8:08am | 735Read More...The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...
-
Sanofi Shares Rise After Company Agrees To Sell Nichi-Iko Pharma Stake
Monday, April 4, 2016 - 10:23am | 264Read More...Shares of Sanofi SA (ADR) (NYSE: SNY) were trading higher by nearly 5 percent on Monday after the company agreed to sell its stake in Japan-based Nichi-Iko Pharma. According to France-based Boursier.com, Sanofi will sell its 4.76 percent stake in Nichi-Iko Pharma which is valued at...
-
Sanofi Is Looking For Rare Disease Acquisitions, FT Says
Monday, February 29, 2016 - 10:21am | 220Read More...Sanofi SA (ADR) (NYSE: SNY) is actively looking to enter the rare disease drugs segment through an acquisition. The Financial Times reported on Sunday that David Meeker, head of Sanofi's Genzyme specialty care business, suggested that rare disease assets represent potential targets as the...
-
EXCLUSIVE: Sanofi In Talks To Buy PTC Therapeutics
Thursday, February 25, 2016 - 2:32pm | 570Read More...Paris-based Sanofi SA (ADR) (NYSE: SNY) has restarted negotiations to acquire New Jersey's PTC Therapeutics, Inc. (NASDAQ: PTCT), a source familiar with the matter told Benzinga on Thursday. Société Générale is said to be working on the deal. Both sides began...
-
Sanofi's Stock Dips Lower Following Q4 Print
Tuesday, February 9, 2016 - 9:11am | 277Read More...Shares of Sanofi SA (ADR) (NYSE: SNY) were trading lower by more than 2 percent early Tuesday morning after the company reported its fourth quarter results. Sanofi said that it earned €1.31 per share in the fourth quarter on revenue of €9.28 billion. Wall Street analysts were expecting the company...
-
Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab
Friday, January 8, 2016 - 11:36am | 180Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) jointly announced Friday morning that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for sarilumab. Regeneron noted that the BLA for sarilumab contains data from...
